Hematology: Thalidomide maintenance in multiple myeloma.
Jacob P
JP
Laubach
Paul G
PG
Richardson
Kenneth C
KC
Anderson
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002882:Chromosomes, Human, Pair 13; D017326:Clinical Trials, Phase III as Topic; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013792:Thalidomide / Q000627:therapeutic use*; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D007166:Immunosuppressive Agents; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin